News
-
-
-
PRESS RELEASE
THX Pharma (Theranexus) and Exeltis secure EMA approval of the paediatric investigation plan (PIP) for TX01, unlocking the PUMA registration pathway
THX Pharma and Exeltis secure 10 years of European market protection for TX01 in Niemann-Pick type C disease with positive PIP approval by EMA's Paediatric Committee (PDCO), paving the way for PUMA submission -
-
PRESS RELEASE
THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day
Join THX Pharma, Biocodex, and BBDF as Platinum Sponsors at the 2026 BDSRA Family Conference to provide an update on the Batten-1 program and Phase 3 study for CLN3 Batten disease -
-
-
PRESS RELEASE
THX Pharma Publishes Its 2025 Annual Results, Cash Position as of March 31, 2026, and Provides a Business Update
THX Pharma announces annual results, cash position, and strategic partnerships, including Biocodex agreement. Financial stability secured. Focus on clinical development and commercialization of TX01 and Batten-1 -
-
